Cancer treatment has rapidly progressed since the development of the first targeted therapies in the 1990s. Prior to that time, hormone and cytotoxic chemotherapies were the mainstays of systemic cancer treatment. In the past ten years, a large number of small molecule targeted therapies and immunotherapies have been approved for use in clinical practice.
Many clinical endocrinologists were familiar with treating glucocorticoid-induced hyperglycemia in patients receiving chemotherapy, and potentially the metabolic consequences of androgen deprivation for prostate cancer, or osteoporosis in women with breast cancer on antiestrogen therapy. However, as the number of approved cancer therapies has increased dramatically, keeping abreast of a large number of chemotherapies, hormonal therapies, small molecule inhibitors, monoclonal antibodies, and immunotherapies in current clinical use and their short and long term endocrine and metabolic effects is increasingly a challenge for clinical endocrinologists.
An important aspect of anticipating and reducing endocrine and metabolic adverse effects is to prevent cancer treatment interruption and avoidable hospitalizations. Obesity and diabetes have been associated with a greater risk of dying from a number of different cancers, and so the metabolic consequences of cancer treatment could in fact contribute to worse cancer outcomes and mortality. Cancer is also becoming a chronic disease, with people potentially living for many years on long-term treatment regimens or on surveillance after completing therapy. Therefore, as time goes on people may be more likely to die with rather than from cancer, and preventing the long-term endocrine / metabolic complications of cancer treatments is likely to become increasingly important.
We welcome the submission of Original Research articles, Perspectives, and Reviews on the following, but not limited to:
- Mechanisms of endocrine or metabolic effects of novel cancer therapies
- Small molecule cancer therapies and their metabolic or endocrine consequences
- Hormonal therapy and short or long term metabolic or endocrine effects
- Cancer treatments and their effects on cachexia
- Endocrine and metabolic issues in survivors of childhood cancers
- Metabolic consequences of cancer treatments and their effects on cancer treatment response
- Effects of metabolic or endocrine disorders/disturbances on cancer outcomes of novel therapies
Cancer treatment has rapidly progressed since the development of the first targeted therapies in the 1990s. Prior to that time, hormone and cytotoxic chemotherapies were the mainstays of systemic cancer treatment. In the past ten years, a large number of small molecule targeted therapies and immunotherapies have been approved for use in clinical practice.
Many clinical endocrinologists were familiar with treating glucocorticoid-induced hyperglycemia in patients receiving chemotherapy, and potentially the metabolic consequences of androgen deprivation for prostate cancer, or osteoporosis in women with breast cancer on antiestrogen therapy. However, as the number of approved cancer therapies has increased dramatically, keeping abreast of a large number of chemotherapies, hormonal therapies, small molecule inhibitors, monoclonal antibodies, and immunotherapies in current clinical use and their short and long term endocrine and metabolic effects is increasingly a challenge for clinical endocrinologists.
An important aspect of anticipating and reducing endocrine and metabolic adverse effects is to prevent cancer treatment interruption and avoidable hospitalizations. Obesity and diabetes have been associated with a greater risk of dying from a number of different cancers, and so the metabolic consequences of cancer treatment could in fact contribute to worse cancer outcomes and mortality. Cancer is also becoming a chronic disease, with people potentially living for many years on long-term treatment regimens or on surveillance after completing therapy. Therefore, as time goes on people may be more likely to die with rather than from cancer, and preventing the long-term endocrine / metabolic complications of cancer treatments is likely to become increasingly important.
We welcome the submission of Original Research articles, Perspectives, and Reviews on the following, but not limited to:
- Mechanisms of endocrine or metabolic effects of novel cancer therapies
- Small molecule cancer therapies and their metabolic or endocrine consequences
- Hormonal therapy and short or long term metabolic or endocrine effects
- Cancer treatments and their effects on cachexia
- Endocrine and metabolic issues in survivors of childhood cancers
- Metabolic consequences of cancer treatments and their effects on cancer treatment response
- Effects of metabolic or endocrine disorders/disturbances on cancer outcomes of novel therapies
